# PROTACs Sector

Canonical URL: https://biopharmsignal.com/sector/protacs

PROTACs includes companies using targeted protein degradation to eliminate disease-causing proteins rather than simply inhibit them. This category is followed closely because it represents a differentiated drug-design strategy with potential advantages in select oncology and immunology settings.

Companies currently grouped under PROTACs: 3

## Recent Sector News

- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-to-report-updated-phase-1a-b-results-for-btk-degrader-bexobrutideg-highlighting-durable-responses-in-relapsed-refractory-cll-sll-and-promising-activity-in-earlier-lines-of-therapy) — Source: Nurix Therapeutics
- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-global-collaboration-with-roche-to-co-develop-and-co-commercialize-potential-best-in-class-btk-degrader-bexobrutideg-across-malignant-hematology-immunology-and-neurology) — Source: Nurix Therapeutics
- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-presents-new-preclinical-and-phase-1-translational-data-supporting-bexobrutideg-nx-5948-in-chronic-spontaneous-urticaria-at-the-2026-society-for-investigative-dermatology-annual-meeting) — Source: Nurix Therapeutics
- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: Nurix Therapeutics
- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-bexobrutideg-oral-presentation-at-the-2026-european-hematology-association-congress) — Source: Nurix Therapeutics
- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-webcast-to-review-new-and-updated-data-from-the-phase-1-clinical-trial-of-btk-degrader-bexobrutideg-nx-5948-to-be-presented-at-the-67th-american-society-of-hematology-ash-annual-meeting-and-exposition) — Source: Nurix Therapeutics
- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-presents-new-data-demonstrating-durable-deepening-responses-in-phase-1-trial-of-bexobrutideg-nx-5948-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll-at-the-67th-american-society-of-hematology-ash-annual-meeting-and-exposition) — Source: Nurix Therapeutics
- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-presents-new-data-from-the-phase-1-trial-of-bexobrutideg-nx-5948-in-waldenstroem-macroglobulinemia-at-the-67th-american-society-of-hematology-ash-annual-meeting-and-exposition) — Source: Nurix Therapeutics
- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference) — Source: Nurix Therapeutics
- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-outlines-2026-goals-and-objectives-for-advancing-bexobrutideg-and-its-pipeline-of-novel-degrader-based-medicines-in-cancer-and-autoimmune-diseases) — Source: Nurix Therapeutics
- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-reports-fourth-quarter-and-fiscal-year-2025-financial-results-and-provides-a-corporate-update) — Source: Nurix Therapeutics
- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-multiple-presentations-showcasing-depth-of-research-pipeline-and-scientific-leadership-at-the-american-association-for-cancer-research-aacr-2026-annual-meeting) — Source: Nurix Therapeutics
- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics to Participate in Upcoming Investor Conference](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-investor-conference) — Source: Nurix Therapeutics
- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-reports-first-quarter-2026-financial-results-and-provides-a-corporate-update) — Source: Nurix Therapeutics
- 2026-06-25 13:46 EST — NRIX — [Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-new-preclinical-data-highlighting-breadth-of-targeted-protein-degradation-pipeline-at-aacr-2026) — Source: Nurix Therapeutics

## Companies

- [CCCC](https://biopharmsignal.com/company/CCCC) — C4 Therapeutics
- [KYMR](https://biopharmsignal.com/company/KYMR) — Kymera
- [NRIX](https://biopharmsignal.com/company/NRIX) — Nurix Therapeutics